Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole-Reference-Cited by-同舟云学术

Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole

Published:2003-12 Issue:12 Volume:18 Page:1392-1398
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J Gastroenterol Hepatol

Author:

ADACHI KYOICHI,HASHIMOTO TOMOYUKI,HAMAMOTO NAOHARU,HIRAKAWA KAZUYA,NIIGAKI MASATOSHI,MIYAKE TATSUYA,TANIURA HIROYUKI,ONO MASAHIRO,KAJI TAKEKAZU,SUETSUGU HIROSHI,YAGI JUNKO,KOMAZAWA YOSHINORI,MIHARA TAKAFUMI,KATSUBE TOMOKO,FUJISHIRO HIROFUMI,SHIZUKU TOSHIHIRO,HATTORI SHUZO,YAMAMOTO SHUN,KINOSHITA YOSHIKAZU

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1440-1746.2003.03190.x/fullpdf

Reference30 articles.

1. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease?

2. Transient lower esophageal sphincter relaxation

3. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

4. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Proton Pump Inhibitors in the Management of Peptic Ulcer;International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN);2023-11-15

2. Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial;Annals of Medicine & Surgery;2023-09-06

3. Cost Avoidance Analysis of Medication Conversions on the Treatment of Gastroesophageal Reflux Disease in a Medication Therapy Management Call Center: A Budgetary Perspective;Journal of Pharmacy Practice;2020-12-15

4. The pathogenesis of persistent non-erosive reflux disease treated with proton-pump inhibitors as measured with the Symptom Index;Esophagus;2014-09-02

5. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole;Alimentary Pharmacology & Therapeutics;2013-09-16